Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Construction in Progress (2021 - 2023)

Grifols' (GIFLF) quarterly Construction in Progress came in at $31.3 million in Q4 2023, up 27.55% on a YoY basis from $24.5 million in Q4 2022, and up 27.55% quarter-over-quarter from $24.5 million in Q4 2022.

Analysis

Grifols (GIFLF) Construction in Progress (2021 - 2023) Analysis & Trends

Grifols (GIFLF) has reported Construction in Progress for 3 consecutive years, with $31.3 million the latest figure, recorded in Q4 2023.

  • For the quarter ending Q4 2023, Construction in Progress rose 27.55% year-over-year to $31.3 million; the trailing twelve-month figure through Dec 2023 stood at $31.3 million (up 27.55% YoY), and the FY2023 full-year result was $31.3 million, up 7.59% from the prior year.
  • Construction in Progress improved to $31.3 million in Q4 2023 per GIFLF's latest filing, from $24.5 million in the prior quarter.
  • Across five years, Construction in Progress topped out at $31.3 million in Q4 2023 and bottomed at $24.5 million in Q4 2022.
  • Historically, Construction in Progress has averaged $27.8 million across 3 years, with a median of $27.5 million in 2021.
  • The sharpest annual moves came in 2022 and 2023: Construction in Progress declined 10.82% in 2022, then grew 27.55% in 2023.
  • Over 3 years, Construction in Progress stood at $27.5 million in 2021, then dropped by 10.82% to $24.5 million in 2022, then advanced by 27.55% to $31.3 million in 2023.
  • According to Business Quant data, Construction in Progress over the past three periods registered $31.3 million, $24.5 million, and $27.5 million for Q4 2023, Q4 2022, and Q4 2021 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn -
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn -
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn -
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn -
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn -
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 31.27 Mn
Dec 31, 2022 24.51 Mn
Dec 31, 2021 27.49 Mn